Unknown

Dataset Information

0

Novel investigational approaches for high-risk genetic subsets of AML: TP53, KMT2A, FLT3.


ABSTRACT: The treatment landscape in acute myeloid leukemia (AML) is rapidly evolving, with multiple new therapies approved in recent years. However, the prognosis for patients with high-risk genetic subsets of AML remains poor, and the development of more effective treatment options for these patients is ongoing. Three of these high-risk AML patient subsets include TP53-mutated AML, FLT3-internal tandem duplication (ITD)-mutated AML, and AML harboring rearrangements affecting the KMT2A locus (KMT2A-r AML). The prognosis for TP53-mutated AML remains poor with both intensive and targeted regimens, including those incorporating the BCL-2 inhibitor, venetoclax. Allogeneic hematopoietic stem cell transplantation is the only potentially curative therapy for these patients, but posttransplant relapse rates remain high. Patients with FLT3-ITD-mutated AML continue to have suboptimal outcomes with standard therapies and experience high rates of relapse following transplant. KMT2A-r AML is also associated with poor outcomes with current treatment approaches, and effective standards of care are lacking for patients with relapsed/refractory disease. This article discusses current treatment approaches, along with the investigational agents being explored for the treatment of these 3 AML subsets, focusing primarily on agents that are further along in development.

SUBMITTER: Sahasrabudhe KD 

PROVIDER: S-EPMC9820850 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

Novel investigational approaches for high-risk genetic subsets of AML: TP53, KMT2A, FLT3.

Sahasrabudhe Kieran D KD   Mims Alice S AS  

Hematology. American Society of Hematology. Education Program 20221201 1


The treatment landscape in acute myeloid leukemia (AML) is rapidly evolving, with multiple new therapies approved in recent years. However, the prognosis for patients with high-risk genetic subsets of AML remains poor, and the development of more effective treatment options for these patients is ongoing. Three of these high-risk AML patient subsets include TP53-mutated AML, FLT3-internal tandem duplication (ITD)-mutated AML, and AML harboring rearrangements affecting the KMT2A locus (KMT2A-r AML  ...[more]

Similar Datasets

| S-EPMC7600363 | biostudies-literature
| S-EPMC11462755 | biostudies-literature
| S-EPMC11694611 | biostudies-literature
| S-EPMC4987127 | biostudies-literature
| S-EPMC4663471 | biostudies-other
| S-EPMC11317385 | biostudies-literature
| S-EPMC8362846 | biostudies-literature
| S-EPMC5519068 | biostudies-other
| S-EPMC8977490 | biostudies-literature
| S-EPMC7073218 | biostudies-literature